Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Access To Investigational Drugs Under FDA Proposed Rule Depends On Size Of Treatment Group

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency also details criteria for charging for investigational drugs in separate proposed rule.

You may also be interested in...



Access To Investigational Drugs Remains Challenge Despite New FDA Rules

FDA has widely publicized ways for patients to get access to investigational trial drugs outside of trials, but there are still many barriers that could hold up implementation in the real world

Access To Investigational Drugs Remains Challenge Despite New FDA Rules

FDA has widely publicized ways for patients to get access to investigational trial drugs outside of trials, but there are still many barriers that could hold up implementation in the real world

FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs

Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS063513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel